Market Overview

UPDATE: Bank of America Downgrades Humana to Neutral on Reimbursement Headwinds

Share:
Related HUM
Look Closer, Tenet Healthcare Is Making More Progress Than It Seems
12 Stocks To Watch For August 2, 2017
Amgen in Collaboration With Humana for Patients' Benefit (GuruFocus)

Bank of America lowered its rating on Humana (NYSE: HUM) from Buy to Neutral and reduced its price objective from $89 to $83.

Bank of America noted, "The operating environment will be more difficult for MA plans under HC Reform and the reimbursement outlook in 2014 and 2015 create significant headwinds during a time period where cost trend is not likely to be as modest as it has been over the past few years, reducing the company's margin for error. However, we expect 2013 guidance has reset the bar low and given HUM's scale and track record, we believe that they will weather this storm better than most."

Humana closed at $76.16 on Tuesday.

Latest Ratings for HUM

DateFirmActionFromTo
Aug 2017Morgan StanleyMaintainsOverweight
Aug 2017Deutsche BankMaintainsHold
Jul 2017Bank of AmericaMaintainsBuy

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!